Good morning to the US, Fanmail (time wise, I am 6h ahead

New Post Public Reply Private Reply Replies (1) Message Board
Zolis_onkel FanMail #34700
565
Good morning to the US, Fanmail (time wise, I am 6h ahead of EST here in Germany, so for me it is already mid afternoon).

To your message:

honestly, my belief is that the CompleteVaccine in fact is "too good" for BigPharma to jump on it. As it is clear as morning air for me, that BigPharma is not interested in the health of their general customer. It is much better to have chronically sick customers, because to such folks they are able to regularly sell their products.
Same way for the mRNA vaccine. Here in Germany our government is currently talking about another Booster shot every 3 to 4 months just to make sure that we are all "well prepared" for the next variant. Same way they are talking about making it mandatory to get vaccinated and serious problems will happen to those, who are still not vaccinated (such as I am). They threaten us with fines, and are even talking about that only the "vaccinated" or "recovered" (the so called 2G rule, as both German words start with a "G" persons are still allowed to go to work (in some potential future that will hopefully never become reality). And even in regards to the "recovered" status, they have recently reduced it from 6 to 3 months. So after a Omicron infection one can only remain without a vaccination for 3 months now, before you would no longer get the benefits of the "2G" status. Why have they changed it to 3 months? Because rumors have it, that a lot of the "unvaccinated" think about having "Corona parties" where they on purpose get themselves infected (believing that an Omicron infection is not as serious as e.g. Delta), to avoid the vaccination.

In this kind of scenario a CompleteVaccine that is claimed to provide immunity for a longer period of time, would not be of interest to such BigPharma companies, as they would only be able to sell dosages of such a vaccine once a year, or maybe even every second, while they can make billions every 3 months with an mRNA vaccine. Why would they get involved with GNBT/NGIO, who may have a superior vaccine? Nobody can make them reliable for the mass occurring serious side effects, and thus it is a license to print money for them, for as long as the CompleteVaccine would not be available.

I know, I know, this does not just sound DISGUSTING, this in fact IS outrageously DISGUSTING, but I am sure that BigPharma companies regularly think that way. Whatever is best for the taxpayers, who are paying the billion dollar bills they hand out to all country governments, does not matter in their eyes, most important is, what is good for them and their shareholders.

The longer I am thinking about this, the more I am convinced that this is what is really going on here. And in conclusion, the reason why GNBT/NGIO likely does not even have a fighting chance (at least in the western world, where these "deep state" players are ruling everything) to be successful with their vaccine development. And in the end it is not Joe Moscato's fault. Heck even the best CEO in the world (who happens to not be involved in the "deep state" games) would not be able to get this working, as it is a steep uphill battle against a very tough/almost impossible to beat opponent.

Regarding your other points about Oral-lyn etc. It all takes money to get these businesses jump started. In the case of Oral-lyn it requires a serious investment in yet another phase III clinical trial. And Joe was not getting tired of always pointing out that he wanted to uplist GNBT to Nasdaq first, before he'd go ahead and raise the required capital to be able to fund this.
In regards to Excellegen, during the May CC it actually sounded as if they were close to getting the required line of credit to get their business jump started. We just don't know what is really going on, as they remained silent ever since, for whatever reason that was.

Regarding your last paragraph, we definitely have a significantly different take on the current situation. I don't think that Joe and the management team really do not care about their subsidiaries or us shareholders. From what I have learned about Joe in the last couple of years is that he may not always make the smartest moves/business decisions, or has the best mannered ways to communicate with us on here, but he definitely thinks that GNBT is "his baby" and will give everything he has to fight for and protect it. And since he has always been very communicative, and I can still recall that one CC where there was a technical issue, and it seem as if nobody was interested in asking questions during the Q&A part of that call. He sounded almost insulted or at least disappointed that nobody seemed to be wanting to ask questions. With that in mind, I absolutely cannot imagine that he remains silent for such a long period of time VOLUNTARILY or because he just couldn't care less. There is no doubt in my mind that there are other reasons why we haven't heard from the company for more than the entire second half of 2021. And that reason might as well be related to first part of my message, meaning this is just yet another part of the measures "deep state" takes to hinder them from being successful with their vaccine development.

This is how I see the current situation.
2

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TCOM Secures $600M Deal to Boost NATO's Defense

Updated Category News Views 3

TCOM's Pivotal $600 Million Defense Contract How often do you hear about a deal north of $600 million that practically revamps a company's strategic future? That's precisely what's hitting the books at TCOM right now. They've scored a heavy-hitting Foreign Military Sales (FMS) contract to fortify NATO's eastern front with Poland. I'll tell you this—it’s one of the...

Continue Reading
Epson & The Photo Managers Highlight Memories in Sept.

Updated Category News Views 8

A Focus on Memory Preservation I remember a time when you kept memories in photo albums, dusty boxes in basements. Now, folks aim to digitize those moments before they're lost forever. With September here, Epson and The Photo Managers are telling us it's time for action. And hey, the campaign’s got a catchy name, 'One Photo, One Story.' Simple, yet it urges us all to...

Continue Reading
Zum Drivers Shine as New School Year Begins

Updated Category News Views 0

Opening the School Year with High Hopes Zum's crew of enthusiastic drivers hit the streets with a mission: kickstarting the new school year with a sense of excitement that feels fresh, even to a grizzled trader like me. These folks are doing more than just turning the ignition, they’re handling a vital cog in the education machine. From Fresno down to Rockford, you’ll...

Continue Reading
MacGregor's Bold Play: RoRo Tech for TT-Line's Ferries

Updated Category News Views 2

A Green Wave in the Baltic It looks like MacGregor's betting big on the future of maritime transport, and they're putting their chips down on TT-Line's next-gen battery-hybrid LNG ferries. With a contract fresh out of the oven, they've signed up to kit out these eco-warriors with a range of RoRo equipment. And let me tell you, this is no piddly order—by any stretch,...

Continue Reading
Supercharged Entertainment's Big Bet in Ohio's Polaris

Updated Category News Views 0

Fasten your seatbelts, folks—because there's a tinge of burnt rubber in the air at Columbus's Polaris Center. Supercharged Entertainment, the big guns in indoor karting, just kicked off construction at their brand-new venue, and it’s looking like a gearhead's paradise. A sprawling 16-acre parcel is set to become a haven for adrenaline junkies come Summer 2027. A Bold...

Continue Reading
Immunic Pushes Boundaries in MS with Vidofludimus

Updated Category News Views 1

Shaking Things Up in Multiple Sclerosis Therapy There's no telling how often the biotech sector tosses around the term 'game-changer,' but when Immunic's name comes up, more ears are perking up these days. The New York-based firm, waving the Nasdaq: IMUX flag, is lining up a virtual shindig come September 9, 2026, and for anyone invested in multiple sclerosis (MS) or...

Continue Reading
Axjo Group Expands in France with Eco-Tourets Buy

Updated Category News Views 6

Seizing the French Market: Axjo's Strategic Play Every now and then, you come across a company that's not just talking the talk but walking the green walk. Axjo Group's latest move—scooping up France's Eco-Tourets—puts them squarely in that league. It ain't just about expanding the footprint; it's about owning a piece of the future where sustainability isn't a...

Continue Reading
Tradr's Bold Venture: Anthropic ETFs Ahead of IPO

Updated Category News Views 2

Why Tradr Is Diving Into Anthropic's Hype There's a whiff of anticipation in the air as Anthropic gears up for its much-anticipated IPO, and Tradr isn't sitting on its hands here. They've just filed for two ETFs—one long, one short—ahead of the big day. We're talking about ANTT and ANTZ, betting on leveraged and inverse plays on whatever whirlwind Anthropic's stock...

Continue Reading
Early Education's Massive Impact: Key Skills for Success

Updated Category News Views 2

Unlocking Lifelong Success: The Early Advantage Ever look at a successful adult and wonder, "Where'd they get that spark?" According to HelloNation and child care expert Karen Ego, it all starts early. Think of early learning not just as prepping for school, but as the first blueprint for life's journey. It's the skills you pick up in those tender years that stick it out...

Continue Reading
Innventure Faces Class Action Over Alleged Deception

Updated Category News Views 3

Unpacking the Innventure Debacle Innventure, Inc. (NASDAQ:INV) seems to have landed itself in hot water, and not the relaxing kind. The revelation that its grand AI data center project in Ontario might never have existed has stirred up quite a storm among shareholders. This isn't just some run-of-the-mill oversight. We're talking about allegations of concocted stories...

Continue Reading

Top 5 Most Recently Viewed Articles

Zealand Pharma A/S Updates Share Count and Voting Rights

Updated Category News Views 86

Zealand Pharma A/S, a key player in the biotech sector out of Copenhagen, confirmed back in early 2024 that it had a total of 71,023,871 shares outstanding. Each share carries a nominal value of DKK 1. This number isn’t just a footnote—it’s vital for any stakeholder keeping tabs on their stake or those considering diving into this space. The company’s compliance...

Continue Reading
CS Genetics Introduces Innovative SimpleCell™ Genomics Kits

Updated Category News Views 146

CS Genetics Launches SimpleCell™ for Enhanced Single-Cell Genomics Single-cell genomics has entered a new era with the exciting launch of SimpleCell™ 3' Gene Expression kits by CS Genetics, a pioneer in the field. This innovative platform simplifies the process of single-cell transcriptomics, making it more accessible and scalable than ever before. The Power of...

Continue Reading
LifeMD's Engagement at the Upcoming Growth Conference

Updated Category News Views 117

LifeMD's Participation in a Major Growth Conference LifeMD, Inc. (Nasdaq: LFMD), a prominent provider in the domain of virtual primary healthcare, has announced its upcoming participation in the Canaccord Genuity 45th Annual Growth Conference. This well-regarded event will take place from August 12 to 14, offering a dynamic platform for dialogue between investors and...

Continue Reading
Exploring Embedded Finance in India: Growth Forecasts to 2029

Updated Category News Views 306

The Future of Embedded Finance in India The embedded finance industry in India is on a remarkable growth trajectory. As we look ahead to the years leading up to 2029, projections indicate a compound annual growth rate (CAGR) of 37.8%, with revenue climbing from US$5.75 billion in 2024 to an impressive US$28.6 billion by the end of the forecast period. Transformative...

Continue Reading
Revolutionizing 3D Modeling: Fixstars Unveils CUMVS Software

Updated Category News Views 179

Revolutionizing 3D Modeling with CUMVS Software Fixstars Corporation, a leader in AI-driven software development, recently made waves with the open-source release of its groundbreaking software, CUMVS (cuda-multi-view-stereo), designed for rapid 3D model generation from 2D images. This innovative software allows users to create digital twins of real-world objects, marking...

Continue Reading